Feb 11, 2026 09:03AM Entera Bio board members purchase shares in open market transactions

Feb 4, 2026 08:02AM OPKO Health and Entera Bio expand partnership for oral PTH tablet

Jan 21, 2026 08:31AM Entera Bio outlines Q1 2026 milestones for osteoporosis drug

Dec 24, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Entera Bio (ENTX)

Dec 22, 2025 08:32AM Entera Bio reports preclinical data for once-daily hypoparathyroidism tablet

Nov 14, 2025 05:43PM Entera Bio Ltd. (ENTX) Tops Q3 EPS by 16c

Sep 25, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Entera Bio (ENTX)

Sep 15, 2025 09:01AM Entera Bio presents oral GLP-2 tablet data at medical conference

Sep 8, 2025 08:32AM Entera Bio presents bone density improvements from EB613 osteoporosis drug

Aug 28, 2025 08:05AM Entera Bio to present clinical data at September medical conferences

Aug 11, 2025 06:42AM Entera Bio Ltd. (ENTX) Tops Q2 EPS by 5c

Jul 8, 2025 08:03AM OPKO Health and Entera Bio abstract selected for ESPEN Congress

Jun 25, 2025 08:05AM OPKO Health (OPK) and Entera Bio (ENTX) Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation

May 30, 2025 04:11PM Entera Bio Ltd. (ENTX) Files $100M Mixed Shelf

May 9, 2025 05:06PM Entera Bio Ltd. (ENTX) Tops Q1 EPS by 1c

Apr 15, 2025 08:32AM Entera Bio Ltd. (ENTX) Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis

Mar 17, 2025 08:01AM OPKO Health (OPK) and Entera Bio (ENTX) Enter into Collaboration Agreement

Oct 7, 2024 06:36AM H.C. Wainwright Reiterates Buy Rating on Entera Bio (ENTX)

Sep 27, 2024 06:51AM H.C. Wainwright Reiterates Buy Rating on Entera Bio (ENTX)

Sep 25, 2024 08:31AM Entera Bio Ltd. (ENTX) and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin Peptide Tablet Candidate